Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Solid Tumours: early-phase trial registry
3 of 4 indexed Advanced Solid Tumours trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Advanced Solid Tumours: 4 US clinical trials tracked, 3 recruiting.
Advanced Solid Tumours is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Impact Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition advanced-solid-tumours
OPEN 3 | RECR 75% | LATE 0 | EARLY 4 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Advanced Solid Tumours lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Solid Tumours on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Solid Tumours is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
First in Human Study of AZD9592 in Solid Tumors
AstraZeneca
NCT05647122
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Pyxis Oncology
NCT06795412
A Study of EBC-129 in Advanced Solid Tumours
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
NCT05701527
IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
Impact Therapeutics
NCT04434482
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Solid Tumours records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Solid Tumours trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Solid Tumours page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Advanced Solid Tumours trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Impact Therapeutics sponsors the most Advanced Solid Tumours trials on record, review their full trial history before evaluating a specific study. See Impact Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Solid Tumours condition card totals 4 registered trials; most-linked intervention IMP4297(senaparib); top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.